Brought to you by 
Acceleron Pharma closes $31mm Series C round
31 Oct 2007
Executive Summary
Acceleron Pharma (therapeutics that modulate the growth of tissues such as bone and muscle) raised $31mm through its Series C financing round led by first-time backer Bessemer Venture Partners. Other new investors MPM BioEquities and QVT Financial were joined by returning shareholders including Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures, Sutter Hill Ventures, and Venrock. The company will use the funds to move its ACE011 bone growth compound into Phase II, begin Phase I trials of ACE031 for muscle growth, and bring its ACE041 angiogenesis candidate into the clinic.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acceleron Pharma closes $31mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice